Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment

European Journal of Cancer

Volumn 42, Issue 2, 2006, Pages 141-148

  Mathijssen, Ron H J ^a   Van Schaik, Ron H N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; CYP; Cytochrome P450; Genotyping; Phenotyping

Indexed keywords

AMFEBUTAMONE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; DOXORUBICIN; EFAVIRENZ; ETOPOSIDE; GEFITINIB; HYDROCORTISONE; IFOSFAMIDE; IMATINIB; KETOCONAZOLE; NAVELBINE; PACLITAXEL; PAROXETINE; TAMOXIFEN; TENIPOSIDE; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER THERAPY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; REVIEW; TREATMENT OUTCOME;

EID: 30544438066     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.08.035     Document Type: Article

References (96)

1. J.D. Watson, and F.H.C. Crick A structure for deoxyribose nucleic acid Nature 171 1953 737 738
2. S. Marsh, and H.L. McLeod Cancer pharmacogenetics Br J Cancer 90 2004 8 11
3. M.V. Relling, and T. Dervieux Pharmacogenetics and cancer therapy Nat Rev Cancer 1 2001 99 108
4. F. Innocenti, and M.J. Ratain Update on pharmacogenetics in cancer chemotherapy Eur J Cancer 38 2002 639 644
5. C.M. Ulrich, K. Robien, and H.L. McLeod Cancer pharmacogenetics: polymorphisms, pathways and beyond Nat Rev Cancer 3 2003 912 920
6. N.F. Smith, W.D. Figg, and A. Sparreboom Recent advances in pharmacogenetic approaches to anticancer drug development Drug Develop Res 62 2004 233 253
7. T. Dervieux, B. Meshkin, and B. Neri Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications Mutation Res 573 2005 180 194
8. A.B. Van Kuilenburg Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil Eur J Cancer 40 2004 939 950
9. M.V. Relling, M.L. Hancock, and G.K. Rivera Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus J Natl Cancer Inst 91 1999 2001 2008
10. H.L. McLeod, and C. Siva The thiopurine S-transferase gene locus - implications for clinical pharmacogenomics Pharmacogenomics 3 2002 89 98
11. F. Innocenti, S.D. Undevia, and L. Iyer Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 2004 1382 1388
12. M.W. Linder, R.A. Prough, and R. Valdes Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency Clin Chem 43 1997 254 266
13. A. Mahgoub, J.R. Idle, and L.G. Dring Polymorphic hydroxylation of debrisoquine in man Lancet 2 1977 584 586
14. F.J. Gonzalez, R.C. Skoda, and S. Kimura Characterization of the common genetic defect in humans deficient in debrisoquine metabolism Nature 331 1988 442 446
15. R.C. Skoda, F.J. Gonzalez, and A. Demierre Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs Proc Natl Acad Sci USA 85 1988 5240 5243
16. 〈www.imm.ki.se/CYPalleles〉; 2005 [accessed 31.07.05].
17. I. Johansson, E. Lundqvist, and L. Bertilsson Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine Proc Natl Acad Sci USA 90 1993 11825 11829
18. C. Sachse, J. Brockmoller, and S. Bauer Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 1997 284 295
19. J.A. Agundez, M.C. Ledesma, and J.M. Ladero Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population Clin Pharmacol Ther 57 1995 265 269
20. M. Bernal, J. Arcocha, and P. Peralta Dystonic movements: a possible secondary effect of gabapentin Rev Neurol 28 1999 1215
21. M.G. Scordo, E. Spina, and G. Facciola Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone Psychopharmacology (Berl) 147 1999 300 305
22. M.H. Cohen, G.H. Williams, and R. Sridhara United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218
23. D. McKillop, A.D. McCormick, and A. Millar Cytochrome P450-dependent metabolism of gefitinib Xenobiotica 35 2005 39 50
24. B. Rochat Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism Clin Pharmacokinet 44 2005 349 366
25. S.S. Dehal, and D. Kupfer CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver Cancer Res 57 1997 3402 3406
26. V. Stearns, M.D. Johnson, and J.M. Rae Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 2003 1758 1764
27. Y. Jin, Z. Desta, and V. Stearns CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 2005 30 39
28. R.H. Van Schaik, E. Teuling, and M. Meijer CYP2C19 genotype predicts duration of response to tamoxifen in advanced breast cancer Clin Pharmacol Ther 77 2005 23 #PI-56
29. S.A. Nowell, J. Ahn, and J.M. Rae Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 2005 249 258
30. P. Wegman, L. Vainikka, and O. Stal Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 2005 R284 R290
31. H.J. Xie, U. Yasar, and S. Lundgren Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation Pharmacogenomics J 3 2003 53 61
32. T.K. Chang, G.F. Weber, and C.L. Crespi Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes Cancer Res 53 1993 5629 5637
33. S. Ren, J.S. Yang, and T.F. Kalhorn Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes Cancer Res 57 1997 4229 4235
34. Z. Huang, P. Roy, and D.J. Waxman Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide Biochem Pharmacol 59 2000 961 972
35. C.S. Chen, Y. Jounaidi, and D.J. Waxman Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450 Drug Metab Dispos 33 2005 1261 1267
36. V. Lamba, J. Lamba, and K. Yasuda Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression J Pharmacol Exp Ther 307 2003 906 922
37. T. Lang, K. Klein, and J. Fischer Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics 11 2001 399 415
38. K. Tsuchiya, H. Gatanaga, and N. Tachikawa Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens Biochem Biophys Res Commun 319 2004 1322 1326
39. J. Kirchheiner, C. Klein, and I. Meineke Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 Pharmacogenetics 13 2003 619 626
40. M. Rotger, S. Colombo, and H. Furrer Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients Pharmacogenet Genomics 15 2005 1 5
41. S. Rodriguez-Novoa, P. Barreiro, and A. Rendon Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects Clin Infect Dis 40 2005 1358 1361
42. J.A. Goldstein Clinical relevance of genetic polymorphisms in the human CYP2C subfamily Br J Clin Pharmacol 52 2001 349 355
43. L. Griskevicius, U. Yasar, and M. Sandberg Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes Eur J Clin Pharmacol 59 2003 103 109
44. T.K. Chang, L. Yu, and J.A. Goldstein Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation Pharmacogenetics 7 1997 211 221
45. Y. Ando, D.K. Price, and W.L. Dahut Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide Cancer Biol Ther 1 2002 669 673
46. S.M. De Morais, G.R. Wilkinson, and J. Blaisdell Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 1994 594 598
47. S.M. De Morais, G.R. Wilkinson, and J. Blaisdell The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 1994 15419 15422
48. J.A. Goldstein, and S.M. de Morais Biochemistry and molecular biology of the human CYP2C subfamily Pharmacogenetics 4 1994 285 299
49. H.G. Xie, H.C. Prasad, and R.B. Kim CYP2C9 allelic variants: ethnic distribution and functional significance Adv Drug Deliv Rev 54 2002 1257 1270
50. N. Bahadur, J.B. Leathart, and E. Mutch CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes Biochem Pharmacol 64 2002 1579 1589
51. A. Soyama, Y. Saito, and K. Komamura Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift Drug Metab Pharmacokin 17 2002 374 377
52. M. Nakajima, Y. Fujiki, and S. Kyo Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 J Clin Pharmacol 45 2005 674 682
53. D. Dai, D.C. Zeldin, and J.A. Blaisdell Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 2001 597 607
54. M. Shou, M. Martinet, and K.R. Korzekwa Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver Pharmacogenetics 8 1998 391 401
55. M.V. Relling, J. Nemec, and E.G. Schuetz O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4 Mol Pharmacol 45 1994 352 358
56. S. Kishi, W. Yang, and B. Boureau Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukaemia Blood 103 2004 67 72
57. J.W. Harris, A. Rahman, and B.R. Kim Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme Cancer Res 54 1994 4026 4035
58. A. Rahman, K.R. Korzekwa, and J. Grogan Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8 Cancer Res 54 1994 5543 5546
59. T. Cresteil, B. Monsarrat, and J. Dubois Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship Drug Metab Dispos 30 2002 438 445
60. X.J. Zhou, X.R. Zhou-Pan, and T. Gauthier Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions Biochem Pharmacol 45 1993 853 861
61. X.R. Zhou-Pan, E. Seree, and X.J. Zhou Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions Cancer Res 53 1993 5121 5126
62. J. Kajita, T. Kuwabara, and H. Kobayashi CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes Drug Metab Dispos 28 2000 1121 1127
63. R.H. Van Schaik Implications of cytochrome P450 genetic polymorphisms on the toxicity of anticancer agents Ther Drug Monit 26 2004 236 240
64. C. Wandel, J.S. Witte, and J.M. Hall CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism Clin Pharmacol Ther 68 2000 82 91
65. D.I. Min, and V.L. Ellingrod Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects Ther Drug Monit 25 2003 305 309
66. D.A. Hesselink, T. van Gelder, and R.H. van Schaik Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes Clin Pharmacol Ther 76 2004 545 556
67. De Jong FA, de Jonge MJ, Verweij J, et al. Role of pharmacogenetics in irinotecan therapy. Cancer Lett [in press].
68. R.H. Mathijssen, S. Marsh, and M.O. Karlsson Irinotecan pathway genotype analysis to predict pharmacokinetics Clin Cancer Res 9 2003 3246 3253
69. R.H. Mathijssen, F.A. de Jong, and R.H. van Schaik Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes J Natl Cancer Inst 96 2004 1585 1592
70. Q. Zhou, A. Sparreboom, and E.H. Tan Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer Br J Clin Pharmacol 59 2005 415 424
71. E. Garcia-Martin, C. Martinez, and R.M. Pizarro CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity Clin Pharmacol Ther 71 2002 196 204
72. B. Amirimani, A.H. Walker, and B.L. Weber RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 91 1999 1588 1590
73. B. Amirimani, B. Ning, and A.C. Deitz Increased transcriptional activity of the CYP3A4*1B promoter variant Environ Mol Mutagen 42 2003 299 305
74. R.H. Van Schaik, M. van der Werf, and I.P. van der Heiden CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population Clin Pharmacol Ther 73 2003 42 #PII-49
75. R.H. Van Schaik, I.P. van der Heiden, and J.N. van den Anker CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 2002 1668 1671
76. D.F. Kehrer, R.H. Mathijssen, and J. Verweij Modulation of irinotecan metabolism by ketoconazole J Clin Oncol 20 2002 3122 3129
77. F.K. Engels, A.J. ten Tije, and S.D. Baker Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel Clin Pharmacol Ther 75 2004 448 454
78. R.H. Mathijssen, J. Verweij, and P. de Bruijn Effects of St. John's wort on irinotecan metabolism J Natl Cancer Inst 94 2002 1247 1249
79. K.T. Kivistö, and H.K. Kroemer Use of probe drugs as predictors of drug metabolism in humans J Clin Pharmacol 37 1997 40s 48s
80. E.C. Dees, and P.B. Watkins Role of cytochrome P450 phenotyping in cancer treatment J Clin Oncol 23 2005 1053 1055
81. P.B. Watkins, S.A. Murray, and L.G. Winkelman Erythromycin breath test as an assay of glucorticoid-inducable liver cytochromes P-450. Studies in rats and patients J Clin Invest 83 1989 688 697
82. J. Hirth, P.B. Watkins, and M. Strawderman The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance Clin Cancer Res 6 2000 1255 1258
83. L.P. Rivory, K.A. Slaviero, and J.M. Hoskins The erythromycin breath test for the prediction of drug clearance Clin Pharmacokinet 40 2001 151 158
84. N. Yamamoto, T. Tamura, and Y. Kamiya Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol J Clin Oncol 18 2000 2301 2308
85. B.C. Goh, S.C. Lee, and L.Z. Wang Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies J Clin Oncol 20 2002 3683 3690
86. K.A. Slaviero, S.J. Clarke, and A.J. McLachlan Population pharmacokinetics of weekly docetaxel in patients with advanced cancer Br J Clin Pharmacol 57 2004 44 53
87. F. Puisset, E. Chatelut, and F. Dalenc Dexamethasone as a probe for docetaxel clearance Cancer Chemother Pharmacol 54 2004 265 272
88. F. Puisset, F. Dalenc, and E. Chatelut Dexamethasone as a probe for vinorelbine clearance Br J Clin Pharmacol 60 2005 45 53
89. M.T. Kinirons, D. O'Shea, and R.B. Kim Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A Clin Pharmacol Ther 66 1999 224 231
90. E.D. Kharasch, K.E. Thummel, and P.B. Watkins CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition Mol Interv 5 2005 151 153
91. J.M. Collins Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans Clin Cancer Res 6 2000 1203 1204
92. E. Rouits, M. Boisdron-Celle, and A. Dumont Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients Clin Cancer Res 10 2004 5151 5159
93. S.J. Gardiner, and E.J. Begg Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 15 2005 365 369
94. M.K. Ma, M.H. Woo, and H.L. McLeod Genetic basis of drug metabolism Am J Health Syst Pharm 59 2002 2061 2069
95. J.W. Watters, and H.L. McLeod Cancer pharmacogenomics: current and future applications Biochim Biophys Acta 1603 2003 99 111
96. S.D. Baker, R.H.N. van Schaik, and L.P. Rivory Factors affecting cytochrome P-450 3A activity in cancer patients Clin Cancer Res 10 2004 8341 8350